New PSC drug enters early safety testing in humans
NCT ID NCT07229911
First seen Nov 17, 2025 · Last updated Jun 15, 2026 · Updated 31 times
Summary
This early-stage study tests whether the experimental drug TAK-781 is safe and tolerable in healthy volunteers and in people with primary sclerosing cholangitis (PSC), a chronic liver disease. The study also looks at how the body processes the drug. About 134 participants will be involved, and the study lasts up to 36 weeks. This is not a cure; it aims to gather safety data for future research.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
ICON
RECRUITINGSalt Lake City, Utah, 84124, United States
Contact
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.